These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 19881535

  • 1. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
    Oncogene; 2010 Feb 04; 29(5):739-51. PubMed ID: 19881535
    [Abstract] [Full Text] [Related]

  • 2. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 04; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 3. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2010 Jan 04; 51(1):421-9. PubMed ID: 19661225
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 5. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
    Chandrasekher G, Sailaja D.
    Invest Ophthalmol Vis Sci; 2004 Oct 07; 45(10):3577-88. PubMed ID: 15452065
    [Abstract] [Full Text] [Related]

  • 6. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
    Fang CX, Yang X, Sreejayan N, Ren J.
    Exp Neurol; 2007 Jan 07; 203(1):196-204. PubMed ID: 16962100
    [Abstract] [Full Text] [Related]

  • 7. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST.
    Cancer Res; 2003 Sep 15; 63(18):5716-22. PubMed ID: 14522890
    [Abstract] [Full Text] [Related]

  • 8. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
    Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA.
    J Cell Biochem; 2010 Feb 01; 109(2):320-8. PubMed ID: 20014066
    [Abstract] [Full Text] [Related]

  • 9. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr 01; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 10. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
    Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA.
    Oncogene; 2005 May 05; 24(20):3257-67. PubMed ID: 15735728
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 12. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 14. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F, Papa V, Libra M, Martinelli G, Cocco L, Martelli AM.
    Cancer Res; 2007 May 01; 67(9):4287-94. PubMed ID: 17483341
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
    Kharas MG, Fruman DA.
    Cancer Res; 2005 Mar 15; 65(6):2047-53. PubMed ID: 15781610
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ, Lledó E, Poch E, Ivorra C, Albero MP, Martínez-Climent JA, Montiel-Duarte C, Rifón J, Pérez-Calvo J, Arbona C, Prósper F, Pérez-Roger I.
    Cancer Res; 2005 Apr 15; 65(8):3264-72. PubMed ID: 15833859
    [Abstract] [Full Text] [Related]

  • 19. Cell invasion of Yersinia pseudotuberculosis by invasin and YadA requires protein kinase C, phospholipase C-gamma1 and Akt kinase.
    Uliczka F, Kornprobst T, Eitel J, Schneider D, Dersch P.
    Cell Microbiol; 2009 Dec 15; 11(12):1782-801. PubMed ID: 19681907
    [Abstract] [Full Text] [Related]

  • 20. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA.
    Expert Opin Investig Drugs; 2009 Sep 15; 18(9):1333-49. PubMed ID: 19678801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.